Investment
Features
FeesSafety
Academy
More
Pluang+

Preferreds credit spreads stay tight; fixed-rate preferreds favored as yields rise post-LIBOR ruling.

Market News
06 Sep 2026
Seeking Alpha
View Source
Bullish
Preferreds credit spreads stay tight; fixed-rate preferreds favored as yields rise post-LIBOR ruling.

Preferred stock and baby bond markets remain stable with tight credit spreads, but yields have increased due to rising long-term interest rates. A key court ruling supports fixed coupons on LIBOR-based preferreds after LIBOR ended, benefiting fixed-rate securities. Saratoga issued a new 8% bond while redeeming older ones to manage liquidity amid high leverage. The merger of MITT and CHMI reduces risk by increasing agency mortgage-backed securities exposure, with some bonds offering attractive yields around 9.2%. These developments highlight cautious optimism and strategic moves in the preferreds and baby bonds sector.

More News

Bitcoin consolidates near $81,500 amid strong ETF inflows and bond market stress.

Bitcoin consolidates near $81,500 amid strong ETF inflows and bond market stress.

Bitcoin reached a four-month high of $81,500 before consolidating, supported by $3.5 billion in August spot Bitcoin ETF inflows and $731 million on Sept. 3 alone. Bond market stress resumed with yields hitting 20-year highs, fueling a narrative of in...

Market News
Bullish
4 hours ago
Applied Aerospace shares drop 35% post-IPO, now valued attractively with growth potential.

Applied Aerospace shares drop 35% post-IPO, now valued attractively with growth potential.

Applied Aerospace & Defense shares have fallen 35% since their IPO, reducing valuations to below 3x sales and 14–15x EBITDA. The company shows improving earnings visibility and a growing $1.13 billion backlog, with second-half revenue guidance indica...

Analyst Insights
Bullish
4 hours ago
Tyra Biosciences downgraded to Hold ahead of key phase 2 trial data for FGFR3-targeting drug.

Tyra Biosciences downgraded to Hold ahead of key phase 2 trial data for FGFR3-targeting drug.

Tyra Biosciences has been downgraded to a Hold rating as it approaches critical phase 2 trial results for its drug dabogratinib, targeting FGFR3-altered IR-NMIBC patients. The company faces significant near-term risks and opportunities from multiple ...

Analyst Insights
Neutral
4 hours ago
Ethena Foundation to release 1.41B ENA tokens from investors on Oct 5, 2026, ending monthly vesting early.

Ethena Foundation to release 1.41B ENA tokens from investors on Oct 5, 2026, ending monthly vesting early.

On October 5, 2026, Ethena Foundation will release approximately 1.41 billion ENA tokens held by original investors in a single event, ending the previous monthly vesting schedule 17 months early. This release represents about 14% of the circulating ...

Protocol Fundamentals
Neutral
4 hours ago
Polestar misses Q2 revenue targets, cuts 2026 growth forecast amid delivery challenges.

Polestar misses Q2 revenue targets, cuts 2026 growth forecast amid delivery challenges.

Polestar reported weaker-than-expected Q2 revenues due to a 4% drop in deliveries, causing an 8.1% year-over-year revenue decline. The company also lowered its production growth forecast for 2026 to a maximum of 5%, reflecting ongoing delivery and pr...

Company Fundamentals
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App